Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients

Fischer SM, Klenske E, Schmitt H, Vitali F, Hirschmann S, Koch F, Ramming A, Zundler S, Nagore D, Uter W, Neurath M, Atreya R (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Journal of Crohns & Colitis Elsevier

Book Volume: 12

Pages Range: S416-S416

DOI: 10.1093/ecco-jcc/jjx180.734

Authors with CRIS profile

Sven Moritz Fischer Department of Paediatrics and Adolescent Medicine Francesco Vitali Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Sebastian Zundler Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Wolfgang Uter Professur für Epidemiologie Markus Neurath Lehrstuhl für Innere Medizin I Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)

Involved external institutions

Progenika Biopharma ES Spain (ES)

How to cite

APA:

Fischer, S.M., Klenske, E., Schmitt, H., Vitali, F., Hirschmann, S., Koch, F.,... Atreya, R. (2018). Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients. (pp. S416-S416).

MLA:

Fischer, Sven Moritz, et al. "Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients." 2018. S416-S416.

BibTeX: Download